Company Description

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA).

The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.

Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah SA

Country	Belgium
Founded	2009
IPO Date	Jul 2, 2021
Industry	Medical Instruments & Supplies
Sector	Healthcare
Employees	184
CEO	Olivier Taelman

Contact Details

Address: Rue Edouard Belin 12 Mont-Saint-Guibert, 1435 Belgium
Phone	32 1 022 23 55
Website	nyxoah.com

Stock Details

Ticker Symbol	NYXH
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	EUR
IPO Price	$30.00
CIK Code	0001857190
ISIN Number	BE0974358906
SIC Code	3841

Key Executives

Name	Position
Olivier Taelman	Chief Executive Officer and Executive Director
Robert Taub MBA	Co-Founder and Chairman
John Landry	Chief Financial Officer
Bruno Onkelinx	Chief Technical Officer
Mikaela Kirkwood	Corporate Communication and Investor Relations Manager
An Moonen	General Counsel
Maggie McGowan	Chief Human Resources Officer
Loic Moreau	President of International
Remi Renard	Chief of Staff
Jeyakumar Subbaroyan	Chief Clinical Officer

Latest SEC Filings

Date	Type	Title
Apr 16, 2025	6-K	Report of foreign issuer
Apr 8, 2025	6-K	Report of foreign issuer
Apr 1, 2025	EFFECT	Notice of Effectiveness
Mar 26, 2025	6-K	Report of foreign issuer
Mar 20, 2025	F-3	Filing
Mar 20, 2025	S-8	Securities to be offered to employees in employee benefit plans
Mar 20, 2025	20-F	Annual and transition report of foreign private issuers
Mar 13, 2025	6-K	Report of foreign issuer
Feb 14, 2025	SCHEDULE 13G	Filing
Jan 2, 2025	6-K	Report of foreign issuer

View All SEC Filings